Evaluation
*
Strongly disagreeDisagreeSlightly disagreeNeitherSlightly agreeAgreeStrongly agree
The activity presented balanced, evidence-based content free of commercial bias.
The presenter(s) used an effective teaching strategy.
The presentation slides / digital materials / resources and handouts were high quality.
The content was relevant to / useful for my professional practice.
The activity contributed to my knowledge, skills, and capacity to enhance the delivery of patient care.
The overall quality of the educational activity was excellent.
*
Strongly disagreeDisagreeSlightly disagreeNeitherSlightly agreeAgreeStrongly agree
Sabiha Khan, MD
Sarah Ikenberry, MA
*
Strongly disagreeDisagreeSlightly disagreeNeitherSlightly agreeAgreeStrongly agree
Describe how biologics differ from small molecules (size, complexity, manufacturing) and explain why some biologics cannot be copied exactly.
Compare and contrast the development, statutory requirements, and approval process for new biologics and for biosimilars/interchangeables.
Explain the requirements for generics and biosimilars/interchangeables.
Identify resources available for health care providers to learn more about biosimilar and interchangeable products through the Purple Book Database of Licensed Biological Products and other FDA educational resources.
*
*
*
*
*
*
*